奥希替尼160 mg治疗EGFR T790M阳性NSCLC中枢神经系统转移的II期多中心双队列研究
该前瞻性单臂双队列II期研究评估奥希替尼160 mg在既往EGFR TKI进展的T790M阳性NSCLC伴脑转移或软脑膜转移患者中的疗效。脑转移队列颅内ORR为55.0%、DCR为77.5%,中位PFS 7.6个月、OS 16.9个月;软脑膜转移队列颅内DCR 92.5%、CR率12.5%,中位OS 13.3个月、PFS 8.0个月,安全性可耐受。
要点
- 奥希替尼160 mg在T790M阳性NSCLC伴脑转移患者中颅内ORR达55.0%,中位PFS 7.6个月。
- 软脑膜转移队列颅内DCR达92.5%,完全缓解率12.5%,中位OS 13.3个月。
- 脑转移队列既往放疗有利于PFS(HR 0.42,P=0.04),安全性以1-2级不良事件为主。
核心结论
- 奥希替尼160 mg在既往EGFR TKI进展的EGFR T790M阳性NSCLC伴中枢神经系统转移患者中显示出有前景的ORR和生存获益,且安全性可耐受。
研究设计与样本
- 前瞻性、单臂、双队列II期研究(NCT03257124),评估奥希替尼160 mg在T790M阳性伴脑转移或软脑膜转移且既往EGFR TKI进展的NSCLC患者中的疗效。
- 脑转移队列主要终点为客观缓解率(H1=30%),软脑膜转移队列主要终点为总生存期(H1=5个月)。
主要发现
- 脑转移队列中位随访10.1个月,颅内ORR为55.0%,DCR为77.5%,中位PFS 7.6个月(95%CI 5.0-16.6),中位OS 16.9个月(95%CI 7.9-NR)。
- 软脑膜转移队列中位随访9.6个月,颅内DCR为92.5%,完全缓解率12.5%,中位OS 13.3个月(95%CI 9.1-NR),中位PFS 8.0个月(95%CI 7.2-NR)。
- 基于既往T790M靶向药物暴露(包括奥希替尼80 mg或其他三代EGFR TKI)的亚组分析显示,脑转移(n=18,P=0.39)和软脑膜转移(n=17,P=0.85)队列的PFS均无差异。
- 脑转移队列中既往放疗有利于PFS(HR 0.42,P=0.04)。
- 最常见不良事件为食欲下降、腹泻和皮疹,但大多为1-2级。
临床怎么用
- 对于既往EGFR TKI进展的EGFR T790M阳性NSCLC伴中枢神经系统转移患者,奥希替尼160 mg可作为考虑的治疗选择之一。
- 脑转移患者若既往接受过放疗,可能从奥希替尼160 mg治疗中获得更优的PFS。
局限性
- 本研究为单臂设计,未设对照,样本量未在摘要中报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Up to 40% of patients with non-small-cell lung cancer (NSCLC) and epidermal growth factor receptor (EGFR) mutations treated with EGFR tyrosine kinase inhibitors (TKIs) present with disease progression in the central nervous system (CNS), either as brain metastases (BM) or leptomeningeal metastases (LM). Osimertinib (80 mg), a third-generation, irreversible, oral EGFR TKI, has shown efficacy in active CNS metastases. However, efficacy of osimertinib 160 mg in BM or LM is unclear. PATIENTS AND METHODS: This prospective, single-arm, two cohort study evaluated the efficacy of osimertinib 160 mg in T790M-positive BM or LM NSCLC patients who progressed on prior EGFR TKI (NCT03257124) treatment. The primary end points were objective response rate (ORR) (H1 = 30%) for the BM cohort and overall survival (OS) (H1 = 5 months) for the LM cohort. RESULTS: The median follow-up duration was 10.1 months and 9.6 months for the BM and LM cohorts, respectively. In the BM cohort, intracranial ORR and disease control rate were 55.0% and 77.5%, respectively. The median progression-free survival (PFS) was 7.6 months [95% confidence interval (CI) 5.0-16.6]; the median OS was 16.9 months [95% CI 7.9-not reached (NR)]. In the LM cohort, intracranial disease control rate was 92.5% and complete response rate was 12.5%. The median OS was 13.3 months (95% CI 9.1-NR); the median PFS was 8.0 months (95% CI 7.2-NR). Subgroup analyses based on previous exposure to T790M-targeting agents, including osimertinib 80 mg or other third-generation EGFR TKIs, showed no difference in PFS in both the BM (n = 18, P = 0.39) and LM (n = 17, P = 0.85) cohorts. Previous radiotherapy favored PFS in the BM cohort (hazard ratio 0.42, P = 0.04). The most common adverse events were decreased appetite, diarrhea, and skin rash; however, most were grade 1-2. CONCLUSION: Thus, osimertinib 160 mg demonstrated promising ORR and survival benefit with a tolerable safety profile in EGFR T790M-positive NSCLC patients with CNS metastasis who progressed on prior EGFR TKIs.
引用
- Park S, Lee MH, Seong M, et al. A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy. Ann Oncol. 2020. PMID: 32634610. doi:10.1016/j.annonc.2020.06.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。